Researchers have uncovered a key mechanism that allows cancer cells to shrug off a promising class of drugs, a finding that could lead to smarter combination therapies and halt drug resistance before it starts. The discovery, published in Cellular and Molecular Biology Letters, explains why BET inhibitors have struggled in clinical trials despite showing strong promise in the lab.
The study, led by scientists at the University of California, Davis, found that when a BET inhibitor eliminates its target protein, BRD4, cancer cells quickly compensate by ramping up production of a related protein called BRD2. This backup protein takes over the epigenetic functions of BRD4, allowing tumors to survive and continue growing. The team analyzed 51 datasets covering cancers including pancreatic, blood, prostate, brain, breast, skin, and lung cancers. In every dataset, treatment with the well-studied BET inhibitor JQ1 was linked to increased BRD2 expression. When the researchers used genetic methods to reduce the cancer cells' ability to produce BRD2, the tumors became far more vulnerable to BET inhibitors.
“If you close a major highway, the traffic doesn’t disappear, it just reroutes,” said first author Suyakarn Archasappawat, a Ph.D. candidate at UC Davis. “BRD2 is the alternative route that cancer cells use when BRD4 is shut down so that they can survive, proliferate, and eventually metastasize.” The findings suggest that a combination treatment targeting both BRD2 and BRD4 simultaneously could block resistance before it takes hold.
A Surprising Clue Opens a New Path Forward
The project began when Archasappawat noticed an unexpected spike in BRD2 levels while analyzing RNA sequencing data from pancreatic cancer cells treated with a BET inhibitor. The pattern was consistent across all eight lab-grown mouse and human cancers the team tested. Senior author Dr. Chang-il Hwang, an associate professor at UC Davis, noted that while BET inhibitors have been in development for years, clinical responses have been modest and short-lived because cancers quickly develop resistance. “Understanding how cancer cells adapt and respond to BET inhibition could reveal vulnerabilities and guide more effective therapies,” he said.
Looking ahead, the researchers say future work should focus on understanding the differences between BRD2 and BRD4 and developing drugs that specifically target BRD2. “Most cancer patients have to undergo multiple rounds of treatment because of drug resistance. It’s almost the expected next step, but I don’t think it has to be inevitable,” Archasappawat said. “If we can identify how cancer cells adapt to resist treatment, we may be able to intercept resistance before it fully locks in.” The study was supported by the National Cancer Institute and other fellowships, offering a hopeful roadmap for more durable cancer therapies.